That's some reimbursement deal: Alexion hikes EPS, sales forecast on French agreement

Save

Here's what a successful negotiation with a government payer will get you: An 18% hike in your earnings forecast, about $150 million in additional sales, and a quick spike in share price. That's what Alexion yielded from a new reimbursement deal with France on its pricey rare disease treatment Soliris.